Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-1 and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-1 and PAI-2 levels were measured by antigenic immunoassays and Cath D by immunoradiometric assay. The median levels of the four parameters were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increases were 4-fold and 5-fold respectively. PAI-1 and PAI-2 increases were much more important, 74-fold and 29-fold respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC stage, tumour size, age, and menopausal status). However, PAI-1 decreased in ER+ and PR+ tumours and PAI-2 increased in menopausal women's tumours. When Cath D, uPA, PAI-1 and PAI-2 levels in malignant tumours were compared, positive correlations were found for all combinations. The implication of plasminogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools other than global antigen measurements in tumours.
Laboratoire d'immunochimie, Centre René Huguenin, Saint-Cloud, France.
D
D
Foucré
C
C
Bouchet
K
K
Hacène
N
N
Pourreau-Schneider
A
A
Gentile
P M
PM
Martin
A
A
Desplaces
J
J
Oglobine
D001941:Breast Diseases / Q000201:enzymology / Q000378:metabolism*; D001943:Breast Neoplasms / Q000201:enzymology / Q000378:metabolism*; D002402:Cathepsin D / Q000378:metabolism*; D005260:Female; D006801:Humans; D015849:Plasminogen Inactivators / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D015849:Plasminogen Inactivators; D014568:Urokinase-Type Plasminogen Activator; D002402:Cathepsin D